August 5, 2023 06:05 AM EDT

FDA clears Biogen, Sage's pill for postpartum depression; What will Roivant, BridgeBio do next?; EQRx becomes history; Non-opioid pain drugs face pivotal moment; and more

Amber Tong

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA clears Biogen, Sage's pill for postpartum depression; What will Roivant, BridgeBio do next?; EQRx becomes history; Non-opioid pain drugs face pivotal moment; and more

Amber Tong

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?

FDA clears Bio­gen, Sage's pill for post­par­tum de­pres­sion; What will Roivant, Bridge­Bio do next?; EQRx be­comes his­to­ry; Non-opi­oid pain drugs face piv­otal mo­ment; and more

Amber Tong

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lex­i­con ends com­mer­cial work to fo­cus on R&D

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

FDA clears Biogen, Sage's pill for postpartum depression; What will Roivant, BridgeBio do next?; EQRx becomes history; Non-opioid pain drugs face pivotal moment; and more

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?